In light of controversy over the recent semaglutide drug shortages for the diabetes patients they're indicated for, one doctor illuminates another side of the case. From the Kardashians to that person ...

Semaglutide, sold under brand names like Ozempic, Rybelsus, and Wegovy, belongs to a class of medications called GLP-1 receptor agonists. While FDA-approved for managing diabetes and aiding weight ...

Wegovy is the brand name for a form of semaglutide that has since been approved for weight loss. Semaglutide, which mimics a natural hormone called GLP-1, helps regulate blood sugar while slowing ...

Orlando, Fla. — Fracture risk in people treated for obesity appears significantly lower with semaglutide (Wegovy) vs sleeve gastrectomy, new data suggest. Previous animal studies have suggested ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

It was the first head-to-head comparison of the injectable GLP-1 medications semaglutide and tirzepatide, which are sold under the brand names Wegovy and Zepbound for weight loss. Roughly 750 ...

Jørgensen pushed the company to prioritize development of semaglutide, a drug that, like Saxenda, mimicked the gut hormone GLP-1. Testing proved it much more powerful, however, with participants in ...

Her openness about her journey, including using the prescription medication semaglutide, sparked a conversation about whether these types of weight loss drugs are truly safe. Kelly Clarkson’s ...

“We can treat it kind of the same way we treated semaglutide and tirzepatide,” the active ingredients in Ozempic and Zepbound. Fritzler says Olympia plans to begin ramping up production this summe ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide highlighted in a letter published in the JAMA Cardiology. The letter is ...

For a time, pharmacies were able to make compounded versions of drugs that had semaglutide or tirzepatide as the active ingredient because of a shortage. In December 2024, the FDA announced that ...